CCO Treatment Updates

The Future of HCV: Small Molecules in Development for Chronic Hepatitis C

Clinical Need and Therapeutic Targets for New HCV Agents

Module 1 of 3

Program Director:
Raymond T. Chung, MD

Faculty:
Kenneth E. Sherman, MD, PhD

CME CREDIT INFORMATION

Release Date: 04/11/07

Expiration Date: 04/10/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Kenneth E. Sherman, MD, PhD, explores the clinical need for novel therapies for chronic hepatitis C. He also reviews the hepatitis C virus life cycle, highlighting the lack of understanding of the mechanism of actions of current agents and the rationale behind specific targeting of the novel small agents in development. The potential for drug resistance based on the specific modes of action of antivirals will be discussed.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss prospective therapeutic targets inherent in the mechanism of hepatitis C virus (HCV) viral replication
Explain the rationale for and potential utility of novel agents under development for the treatment of HCV
Describe HCV antiviral resistance that may develop with certain novel therapeutics

Investigational Small Molecule Agents for the Treatment of Chronic Hepatitis C

Module 2 of 3

Program Director:
Raymond T. Chung, MD

Faculty:
Gary L. Davis, MD

CME CREDIT INFORMATION

Release Date: 07/16/07

Expiration Date: 07/15/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Gary L. Davis, MD, discusses the latest efficacy and safety data from small-molecule, specifically targeted, anti-HCV agents in development.

Learning Objectives

Upon completion of this activity, participants should be able to:

List steps in the hepatitis C virus (HCV) life cycle that present opportunities for therapeutic intervention
Discuss emerging efficacy and safety data on small-molecule specifically targeted anti-HCV agents
Describe the current understanding of resistance mutations with new therapies

Current Issues in the Development and Clinical Role of Novel Agents for Chronic Hepatitis C

Module 3 of 3

Program Director:
Raymond T. Chung, MD

Faculty:
Raymond T. Chung, MD

CME CREDIT INFORMATION

Release Date: 08/27/07

Expiration Date: 08/26/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Raymond T. Chung, MD, explores key issues in the development and potential future clinical role of small-molecule anti–hepatitis C virus (HCV) agents with particular emphasis on HCV drug resistance.

Learning Objectives

Upon completion of this activity, participants should be able to:

List considerations related to future clinical trial design for small-molecule agents
Describe the continued role of standard of care agents with small-molecule targeted agents
Discuss the potential timing for the use of novel agents in hepatitis C virus–infected patients in different patient types

Print-on-Demand Monograph

CCO Print on Demand: Download a PDF of The Future of HCV: Small Molecules in Development for Chronic Hepatitis C monograph.

Print On Demand

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.